# US 2021/0275611 A1 · Composition for use in the treatment of major depressive disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275611 A1
- Document ID: US20210275611A1
- Status: Published application
- Kind: A1
- Application number: 16/321,405
- Filed: 2017-08-10
- Published: 2021-09-09
- Earliest claimed: 2016-08-10
- Assignees: Probiotical S.P.A.
- Applicants: Probiotical S.P.A.
- Inventors: Giovanni MOGNA
- Web page: https://patentgrep.com/patent/US20210275611A1

## CPC

- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/59: Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/30: Zinc; Compounds thereof
- A61K 35/745: Bifidobacteria
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to a composition for use in the treatment of major depressive disorder. In addition, this invention relates to a composition for use in the treatment and/or improvement of mood disturbances and for use in the treatment and/or improvement of the mood state.

## Claims

### Claim 1

A mixture of bacterial strains comprising or, alternatively, consisting of at least one bacterial strain selected from the group comprising or, alternatively, consisting of:
a bacterial strain belonging to the species Lactobacillus fermentum, such as the bacterial strain Lactobacillus fermentum LF16 DSM 26956; and/or
a bacterial strain belonging to the species Lactobacillus plantarum, such as the bacterial strain Lactobacillus plantarum LP01 LMG P-21021; and/or
a bacterial strain belonging to the species Lactobacillus plantarum, such as the bacterial strain Lactobacillus plantarum LP02 LMG P-21020; and/or
a bacterial strain belonging to the species Lactobacillus rhamnosus, such as the bacterial strain Lactobacillus rhamnosus LR06 DSM 21981; and/or
a bacterial strain belonging to the species Bifidobacterium longum, such as the bacterial strain Bifidobacterium longum BL04 DSM 23233;
said mixture being for use in the treatment and/or improvement of a major depressive disorder, of a mood disorder or the mood state.

### Claim 2 (depends on 1)

The mixture for use according to claim 1, wherein said mixture comprises or, alternatively, consisting of:
a bacterial strain belonging to the species Lactobacillus fermentum, such as the bacterial strain Lactobacillus fermentum LF16 DSM 26956; and
a bacterial strain belonging to the species Lactobacillus plantarum, such as the bacterial strain Lactobacillus plantarum LP01 LMG P-21021 and/or a bacterial strain belonging to the species Lactobacillus plantarum, such as the bacterial strain Lactobacillus plantarum LP02 LMG P-21020; and
a bacterial strain belonging to the species Lactobacillus rhamnosus, such as the bacterial strain Lactobacillus rhamnosus LR06 DSM 21981; and
a bacterial strain belonging to the species Bifidobacterium longum, such as the bacterial strain Bifidobacterium longum BL04 DSM 23233; preferably in a weight ratio equal to 1:1:1:1 or equal to 1:1:1:1:1.

### Claim 3 (depends on 1)

A composition for use in the treatment and/or improvement of a depressive disorder, a mood disorder, or the mood state; said composition comprises the mixture according to claim 1.

### Claim 4 (depends on 3)

The composition for use according to claim 3, wherein said composition comprises a mixture that comprises or, alternately, consists of:
(a) at least one bacterial strain selected from a first group of strains;
(b) at least one vitamin selected from a second group of vitamins;
(c) at least one salt selected from a third group of organic and/or inorganic salts;
(d) at least one substance selected from a fourth group of antioxidant substances and, optionally, technological additives and/or pharmaceutical or food grade excipients.

### Claim 5 (depends on 4)

The composition for use according to claim 4, wherein said first group of compounds comprises or, alternately, consists of: (a-i) a combination consisting of a natural, vegetable gum, such as tara gum and the bacterial strain S. thermophilus ST10 DSM 25246; (a-ii) a bacterial strain belonging to the species Lactobacillus fermentum, such as the bacterial strain Lactobacillus fermentum LF16 DSM 26956; (a-iii) a bacterial strain belonging to the species Lactobacillus plantarum, such as the bacterial strain Lactobacillus plantarum LP02 LMG P-21020; (a-iv) a bacterial strain belonging to the species Lactobacillus rhamnosus, such as the bacterial strain Lactobacillus rhamnosus LR06 DSM 21981; (a-v) a bacterial strain belonging to the species Bifidobacterium longum, such as the bacterial strain Bifidobacterium longum BL04 DSM 23233; preferably each single strain being present in a concentration comprised from 1×108CFU to 1×1012 CFU, compared to the daily dose, it is preferably present in a concentration comprised from 1×109 CFU to 1×1011 CFU, compared to the daily dose.

### Claim 6 (depends on 4)

The composition for use according to claim 4, wherein said second group of vitamins comprises or, alternatively, consists of: (b-i) C group vitamins; (b-ii) E group vitamins; (b-iii) B group vitamins; and (b-iv) D group vitamins; preferably each single vitamin being present in an amount equal to 100%.

### Claim 7 (depends on 4)

The composition for use, according to any one of the claims 4, wherein said third group of organic and/or inorganic salts comprises, or alternatively, consists of: (c-i) organic and/or inorganic magnesium salts; (c-ii) organic and/or inorganic selenium salts; or (c-iii) organic and/or inorganic zinc salts.

### Claim 8 (depends on 7)

The composition for use according to claim 7, wherein said magnesium salt (c-i) is preferably magnesium glycinate; said selenium salt (c-ii) is preferably selenium methionine and said zinc salt (c-iii) is preferably zinc gluconate; preferably each single vitamin being present in an amount of 100%.

### Claim 9 (depends on 4)

The composition for use according to any of the claims 4, wherein said fourth group of antioxidant substances comprises or, alternatively, consists of: (d-i) N-acetyl cysteine (NAC); (d-ii) Coenzyme Q10 (CoQ10); and (d-iii) L-Acetylcarnitine ALC; preferably each single antioxidant substance being present in a quantity of 100 mg/day.

### Claim 10

A method for the treatment and/or improvement of a major depressive disorder, of a mood disorder or the mood state of a subject, comprising orally administering mixture of bacterial strains to the subject, wherein the mixture comprises or, alternatively, consists of at least one bacterial strain selected from the group comprising or, alternatively, consisting of:
a bacterial strain belonging to the species Lactobacillus fermentum, such as the bacterial strain Lactobacillus fermentum LF16 DSM 26956; and/or
a bacterial strain belonging to the species Lactobacillus plantarum, such as the bacterial strain Lactobacillus plantarum LP01 LMG P-21021; and/or
a bacterial strain belonging to the species Lactobacillus plantarum, such as the bacterial strain Lactobacillus plantarum LP02 LMG P-21020; and/or
a bacterial strain belonging to the species Lactobacillus rhamnosus, such as the bacterial strain Lactobacillus rhamnosus LR06 DSM 21981; and/or
a bacterial strain belonging to the species Bifidobacterium longum, such as the bacterial strain Bifidobacterium longum BL04 DSM 23233.

### Claim 11 (depends on 10)

The method of claim 10, wherein said mixture comprises or, alternatively, consisting of:
a bacterial strain belonging to the species Lactobacillus fermentum, such as the bacterial strain Lactobacillus fermentum LF16 DSM 26956; and
a bacterial strain belonging to the species Lactobacillus plantarum, such as the bacterial strain Lactobacillus plantarum LP01 LMG P-21021 and/or a bacterial strain belonging to the species Lactobacillus plantarum, such as the bacterial strain Lactobacillus plantarum LP02 LMG P-21020; and
a bacterial strain belonging to the species Lactobacillus rhamnosus, such as the bacterial strain Lactobacillus rhamnosus LR06 DSM 21981; and
a bacterial strain belonging to the species Bifidobacterium longum, such as the bacterial strain Bifidobacterium longum BL04 DSM 23233; preferably in a weight ratio equal to 1:1:1:1 or equal to 1:1:1:1:1.

### Claim 12 (depends on 10)

The method of claim 10, wherein said mixture comprises or, alternately, consists of:
(a) at least one bacterial strain selected from a first group of strains;
(b) at least one vitamin selected from a second group of vitamins;
(c) at least one salt selected from a third group of organic and/or inorganic salts;
(d) at least one substance selected from a fourth group of antioxidant substances and, optionally, technological additives and/or pharmaceutical or food grade excipients.

### Claim 13 (depends on 12)

The method of claim 12, wherein said first group of strains comprises or, alternately, consists of: (a-i) a combination consisting of a natural, vegetable gum and the bacterial strain S. thermophilus ST10 DSM 25246; (a-ii) a bacterial strain belonging to the species Lactobacillus fermentum; (a-iii) a bacterial strain belonging to the species Lactobacillus plantarum; (a-iv) a bacterial strain belonging to the species Lactobacillus rhamnosus; (a-v) a bacterial strain belonging to the species Bifidobacterium longum; each single strain being present in a concentration comprised from 1×108 CFU to 1×1012 CFU, compared to the daily dose.

### Claim 14 (depends on 12)

The method of claim 12, wherein said second group of vitamins comprises or, alternatively, consists of: (b-i) C group vitamins; (b-ii) E group vitamins; (b-iii) B group vitamins; and (b-iv) D group vitamins.

### Claim 15 (depends on 12)

The method of claim 12, wherein said third group of organic and/or inorganic salts comprises, or alternatively, consists of: (c-i) organic and/or inorganic magnesium salts; (c-ii) organic and/or inorganic selenium salts; or (c-iii) organic and/or inorganic zinc salts.

### Claim 16 (depends on 15)

The method of claim 15, wherein said magnesium salt (c-i) is magnesium glycinate; said selenium salt (c-ii) is selenium methionine and said zinc salt (c-iii) is zinc gluconate.

### Claim 17 (depends on 12)

The method of claim 12, wherein said fourth group of antioxidant substances comprises or, alternatively, consists of: (d-i) N-acetyl cysteine (NAC); (d-ii) Coenzyme Q10 (CoQ10); and (d-iii) L-Acetylcarnitine ALC.
